Table 5. Analytical sensitivity evaluation results of the Kaira assay.
| Target concentration | SARS-CoV-2 | Influenza A | Influenza B | RSV | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Copies/mL | Replicates | Detected | Copies/mL | Replicates | Detected | Copies/mL | Replicates | Detected | Copies/mL | Replicates | Detected | |
| #1 | 2500 | 20 | 20 | 3500 | 20 | 20 | 2400 | 20 | 20 | 4000 | 20 | 20 |
| #2 | 1250 | 20 | 20 | 1750 | 20 | 20 | 1200 | 20 | 20 | 2000 | 20 | 20 |
| #3 | 500 | 20 | 20 | 700 | 20 | 18 | 480 | 20 | 20 | 800 | 20 | 20 |
| #4 | 250 | 20 | 20 | 350 | 20 | 0 | 240 | 20 | 17 | 400 | 20 | 18 |
| #5 | 50 | 20 | 12 | 70 | 20 | 0 | 48 | 20 | 3 | 80 | 20 | 11 |
| #6 | 25 | 20 | 7 | 35 | 20 | 0 | 24 | 20 | 0 | 40 | 20 | 8 |
| #7 | 12.5 | 20 | 5 | 17.5 | 20 | 0 | 12 | 20 | 1 | 20 | 20 | 2 |
| Probit LOD (copies/mL) | 106.1 | 717.1 | 287.3 | 442.9 | ||||||||